Lyra Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the treatment of patients with chronic rhinosinusitis (CRS). Co.'s technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Co.'s product candidates, LYR-210, which is designed to treat CRS patients both with and without nasal polyps who have failed previous medical management and have not undergone endoscopic sinus surgery; and LYR-220, which is also designed to utilize mometasone furoate, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. The LYRA stock yearly return is shown above.
The yearly return on the LYRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LYRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|